Peter Bross
Impact in
- Hematology top 2%
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Oncology top 5%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
Papers in
- Oncology 6
- Cancer Treatment and Pharmacology 2
- Cancer Immunotherapy and Biomarkers 2
- CAR-T cell therapy research 2
- Co-authors
- Richard Pazdur (6 shared papers)Robert C. Kane (1 shared paper)Ann T. Farrell (1 shared paper)Atiqur Rahman (4 shared papers)Gang Chen (2 shared papers)Grant Williams (2 shared papers)Julie Beitz (1 shared paper)Eamon Duffy (1 shared paper)
- Journals
- Clinical Cancer Research (2 papers)The Oncologist (2 papers)Urologic Oncology Seminars and Original Investigations (1 paper)Journal for ImmunoTherapy of Cancer (1 paper)Pharmacogenomics (1 paper)
- Partner nations
- United StatesThailandSwitzerland
In The Last Decade
Peter Bross
12 papers receiving 1.4k citations
Peter Bross's Hit Papers
Peers
Comparison fields: 5 of 91
- Hematology 435
- Oncology 562
- Radiology, Nuclear Medicine and Imaging 278
- Genetics 109
- Molecular Biology 649
Countries citing papers authored by Peter Bross
This map shows the geographic impact of Peter Bross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Bross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Bross more than expected).
Fields of papers citing papers by Peter Bross
This network shows the impact of papers produced by Peter Bross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Bross. The network helps show where Peter Bross may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Bross, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Hit paper breakdown → | 2001 | 708 |
| 2 | Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy Hit paper breakdown → | 2003 | 519 |
| 3 | Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. | 2003 | 87 |
| 4 | 2002 | 63 | |
| 5 | Fulvestrant in postmenopausal women with advanced breast cancer. | 2003 | 46 |
| 6 | 2013 | 20 | |
| 7 | 2024 | 14 | |
| 8 | 2008 | 13 | |
| 9 | 2014 | 6 | |
| 10 | 1999 | 5 | |
| 11 | 2025 | 2 | |
| 12 | Report from the FDA Approval Summary: Imatinib Mesylate Capsules for Treatment of Adult Patients with Newly Diagnosed Philadelphia Chromosome- positive Chronic Myelogenous Leukemia in Chronic Phase | 2003 | 1 |
| 13 | 2023 | 0 | |
| 14 | 2019 | 0 |
About Peter Bross
Peter Bross is a scholar working on Oncology, Molecular Biology, Hematology, Surgery and Pharmacology, having authored 14 papers that have together received 1.5k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (2 papers), Estrogen and related hormone effects (2 papers), Cancer Treatment and Pharmacology (2 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), CAR-T cell therapy research (2 papers), Bladder and Urothelial Cancer Treatments (2 papers) and Pharmacogenetics and Drug Metabolism (1 paper). The work is most often cited by research in Hematology (435 citations), Oncology (562 citations), Radiology, Nuclear Medicine and Imaging (278 citations), Genetics (109 citations) and Molecular Biology (649 citations). Peter Bross has collaborated with scholars based in United States, Thailand and Switzerland. Frequent co-authors include Richard Pazdur, Robert C. Kane, Ann T. Farrell, Atiqur Rahman, Gang Chen, Grant Williams, Julie Beitz, Eamon Duffy, R N Sridhara and Sandip Kumar Roy. Their work appears in journals such as Clinical Cancer Research, The Oncologist, Urologic Oncology Seminars and Original Investigations, Journal for ImmunoTherapy of Cancer and Pharmacogenomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.